Enter food therapy—a gentle, empowering approach that harnesses the power of everyday edibles to address root causes like ...

Hives often fade within a day and never come back. But chronic hives appear almost daily for six or more weeks.

Levels of haptoglobin in serum may help predict which patients with chronic spontaneous urticaria will achieve complete ...

Impaired sleep had an effect on perception of disease severity in patients with chronic urticaria in the study. Higher ...

In patients with chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines, re-treatment with ligelizumab was effective and mostly well tolerated, with both 72-mg and 120-mg doses yielding ...

Thanks to climate change, fall allergy season starts 20 days earlier and is 21% more intense than 30 years ago, according to research published by the National Academy of Sciences. And allergy ...

In September 2025, the US Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral small molecule kinase inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in ...

UNDERSTANDING what matters most to patients with chronic urticaria is vital to delivering care that truly reflects their needs and priorities. A new systematic review, encompassing 18 studies and over ...

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with ...

EAST HANOVER, N.J., Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido ® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult ...